|Quantity Discounts||1 - 9999|
|1 - 9999|
|1 - 9999|
FDA has new money budgeted for these crackdowns, known officially as the “Postmarket Adverse Drug Experience Inspectional Program.” And it’s not just U.S. companies facing the pharmacovigilance cops. Health Canada, for instance, is reported to be tacking pharmacovigilance inspections on the end of traditional GMP inspections.
In a fast-paced 90-minute Encore presentation, you and your staff will glean essential guidance on preparing in advance for pharmacovigilance inspections ... how to manage the investigation itself ... and most importantly, how to bring the matter to a close with no nasty aftershocks — such as 483s, warning letters ... even seeing clinical trials suspended and drugs pulled from market when violations are serious enough.
Pharmacovigilance investigators are likely to shine the spotlight without warning on staff who’ve never dealt with inspections too. Make sure your “newbies” are on hand for tips, advice and guidance on how to deal with these inspections. It could save your organization time, hassles — and actual dollars.
You and your entire staff will get the answers you need to pressing questions such as:
Improper risk management and drug safety can result in financial losses, substantial penalties, legal fees and worse. It can bring product approvals to a screeching halt. Add in the potential bad press and loss of reputation, and the risk simply becomes too great. Make sure your key staff — both new and experienced — are on hand for this timely presentation. It’s ideal for:
Barbro Westin, M.Sc. Ph.M., is Director, Pharmacovigilance at CanReg, Inc. Barbro has more than twenty years experience in the pharmaceutical industry with extensive knowledge of reporting regulations for adverse events in the United States, Canada and Europe with a focus on medical information and drug safety surveillance. She prepares clients, ranging from small biotechnical to large pharmaceutical companies, for inspections by health authorities ensuring compliance with appropriate regulations for pharmacovigilance commitments.Irma Monaco, B.Sc., PT, is Associate Director, Medical Information at CanReg, Inc. Irma has more than 10 years of experience working with clients on issues with pharmacovigilance and medical information. She develops SOPs and ensures the compliance of clients with appropriate regulations for client’s pharmacovigilance commitments. She is a frequent trainer at many industry events.
|Date:||July 6–24, 2009|
|Location:||Your office or conference room (no need to travel!)|
Gather your team for maximum benefit! Your investment is for one dial-in.
We accept American Express, Visa and MasterCard. Make checks payable to FDAnews.
Or, register by phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600
Registrations may not be cancelled. Please contact customer service to make any substitutions.
Interested in Becoming a Speaker?
We're always looking for industry leaders eager to share their expertise at an FDAnews audioconference, webinar or physical conference. Our seasoned speaker community includes executives in the pharmaceutical, medical device and clinical trial industries, regulatory affairs, quality control, compliance, healthcare and academia, as well as several former — and current — top FDA officials. Click here to complete our speaker opportunity form and have a representative contact you about future opportunities.
Copyright ©2018. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing